home.aspx
 
EVENTS

SiriusDecisions 2019 Technology Exchange
SIRIUSDECISIONS 2019 TECHNOLOGY EXCHANGE
December 09-11, 2019
The drive for growth never ceases for b-to-b organizations, and more than ever technology is at the centre of enabling that progress. Gone are the days however when a disparate, disconnected set of platforms strewn across sales, marketing an product can serve the organization effectively. An aligned...

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...

Cancer IQ, Inc.

CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease.

RELATED NEWS


Cancer Research UK has announced that incidences of melanoma have increased by 45% since 2004. Latest figures show that rates have increased by more than a third 35% for women and by almost three-fifths 55% for men, and that rates for 25-49 year-olds have increased by as much as 70% since the 1990s. Despite these rising figures, melanoma is still most prevalent in those over 65. The figures have been released to mark the launch of the charity’s Own Your Tone campaign which encourages peopl...

READ MORE

A study published by The BMJ has reported a possible association between higher consumption of sugary drinks and and an increased risk of cancer. The data comes from a team of researchers based in France, who set out to assess the associations between the consumption of sugary drinks (sugar sweetened beverages and 100% fruit juices), artificially sweetened beverages, and risk of overall cancer, as well as breast, prostate, and bowel cancers. The results show that a 100 ml per day increase in the...

READ MORE

The largest ever study of advanced prostate cancer genomics has revealed that men with mutations in the retinoblastoma gene in their tumours were more than three times as likely to die and nearly seven times as likely to relapse on standard treatments as those without the gene. Scientists identified the gene mutation in the tumours of men, which could help to pick out patients for more intensive treatment in the future. The gene in question – the retinoblastoma gene – is known as RB1...

READ MORE

Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) will not be available to advanced bladder cancer patients for at least three years in much of the UK after NICE published final guidance that rejected the drug for regular NHS funding in this use. Following its usual review process, NICE concluded in final guidance that Opdivo is not cost-effective for treating local advanced unresectable or metastatic urothelial cancer, after platinum-based chemotherapy....
PHARMAPHORUM
READ MORE

Roche is hoping its Tecentriq will be the first immunotherapy approved in tough-to-treat breast cancer after it stayed the spread of “triple negative” disease in a phase 3 trial. When combined with Celgene’s chemotherapy Abraxane (nab-paclitaxel) Tecentriq produced a statistically significant improvement in progression-free survival compared with chemotherapy, in PD-L1 positive first-line metastatic triple negative breast cancer (TNBC) patients. An interim analysis showed an en...
PHARMAPHORUM MEDIA LIMITED
READ MORE

As the opioid epidemic continues to be a grave concern for many across the world some scientists in Israel have been looking at the efficacy of medical cannabis for cancer pain; significant findings included a reduction or elimination (in some cases) of opioid use.  The study, published in the European Journal of Internal Medicine, is one of the largest in size because of the differences in medical marijuana laws in Israel.  The medical marijuana program is supported by government and ...
LABROOTS
READ MORE

Apexian Pharmaceuticals is pleased to announce that the National Cancer Institute (NCI) has selected the company to participate in its highly competitive Small Business Innovation Research (SBIR) Investor Initiatives program, that encourages domestic small businesses to engage in Research and Development (R&D) that has the potential for commercialization....

READ MORE

It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use. The National Institute for Health and Care Excellence said it is not recommending NHS funding for Kisplyx (lenvatinib) in combination with everolimus for previously treated patients because of uncertainties in the clinical evidence. While trial data suggest...

READ MORE

Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research led by Nada Kalaany, PhD, at Boston Children's Hospital and the Broad Institute of MIT and Harvard, now suggests a novel approach to treating this deadly cancer: targeting an enzyme that tumors use to get rid of nitrogen. The study, published online in Nature Communicati...

READ MORE

A new report on the prospects of immunotherapy treatments has identified smaller, nimble biotechs and early stage companies as the single biggest factor behind the next generation of approaches in development. The report concludes that the next five years will be the most promising in the fight against cancer with immunotherapies – such as CAR-T and moderating T-Cell approaches, and innate immunity therapies – delivering far better patient outcomes. The Inside Perspectives: Will Immunotherapy Kn...

READ MORE

EVENTS

eyeforpharma Awards 2019
EYEFORPHARMA AWARDS 2019
December 11-11, 2019
You’ll already know if you’re a winner: your patients are telling you. But now it’s time to be recognised by your peers and the wider healthcare community. The eyeforpharma awards are unique. They’re the only awards that focus exclusively on what matters - value for patients ...

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...